Showing results (441-450 of 4,634) with videos related to

Sort By:
Pageof 464
Anti-Cancer Drugs|March 26, 2009
Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenograftsMu Zhang, Weiyang Tao, Shangha Pan, et al.
Anti-Cancer Drugs|March 26, 2009
A patient with huge hepatocellular carcinoma who had a complete clinical response to p53 gene combined with chemotherapy and transcatheter arterial chemoembolizationGeng Tian, Jiliang Liu, Jie Sui
Anti-Cancer Drugs|July 14, 2009
Methotrexate-induced apoptosis is enhanced by altered expression of methylenetetrahydrofolate reductaseBasak Celtikci, Andrea K Lawrance, Qing Wu, et al.
Anti-Cancer Drugs|April 17, 2009
Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell linesMarcel N A Bijman, Maria P A van Berkel, Mirjam Kok, et al.
Anti-Cancer Drugs|February 11, 2010
Celecoxib activates Stat5 and restores or increases the expression of growth hormone-regulated genes in hepatocarcinogenesisJaime Arellanes-Robledo, Martha Estela Salcido-Neyoy, Adriana Márquez-Quiñones, et al.
Anti-Cancer Drugs|February 12, 2010
Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell linesHenning Lünenbürger, Claudia Lanvers-Kaminsky, Birgit Lechtape, et al.
Anti-Cancer Drugs|February 20, 2010
Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cellsLars Ekblad, Johan Kjellström, Anders Johnsson
Anti-Cancer Drugs|September 10, 2016
Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumorsSandrine Aspeslagh, Ahmad Awada, Arturo S Matos-Pita, et al.
Anti-Cancer Drugs|September 9, 2016
Differential receptor dependencies: expression and significance of muscarinic M1 receptors in the biology of prostate cancerAbdul Mannan Baig, Naveed A Khan, Vardah Effendi, et al.
Anti-Cancer Drugs|August 25, 2016
The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancerAdriana Romiti, Michela Roberto, Chiara D'Antonio, et al.
Pageof 464